Business Description
![Akebia Therapeutics Inc Akebia Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000AKPK.png?14)
Akebia Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00972D1054
Description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.8 | |||||
Equity-to-Asset | -0.15 | |||||
Debt-to-Equity | -1.47 | |||||
Debt-to-EBITDA | 10.7 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -9.31 | |||||
Beneish M-Score | -2.15 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -21.3 | |||||
3-Year EBITDA Growth Rate | 73.9 | |||||
3-Year EPS without NRI Growth Rate | 53.7 | |||||
3-Year FCF Growth Rate | 46.1 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 74.52 | |||||
9-Day RSI | 67.81 | |||||
14-Day RSI | 64.12 | |||||
6-1 Month Momentum % | -4.64 | |||||
12-1 Month Momentum % | 25.22 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.04 | |||||
Quick Ratio | 0.82 | |||||
Cash Ratio | 0.37 | |||||
Days Inventory | 116.71 | |||||
Days Sales Outstanding | 57.66 | |||||
Days Payable | 64.19 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.5 | |||||
Shareholder Yield % | 3.25 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 62.56 | |||||
Operating Margin % | -20.11 | |||||
Net Margin % | -23.18 | |||||
FCF Margin % | -22.33 | |||||
ROA % | -17.19 | |||||
ROIC % | -19.37 | |||||
ROC (Joel Greenblatt) % | -180.69 | |||||
ROCE % | -22.56 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.71 | |||||
EV-to-EBIT | -10.13 | |||||
EV-to-EBITDA | 72.12 | |||||
EV-to-Revenue | 1.91 | |||||
EV-to-Forward-Revenue | 1.88 | |||||
EV-to-FCF | -8.51 | |||||
Earnings Yield (Greenblatt) % | -9.87 | |||||
FCF Yield % | -12.19 |